The USPTO approved a patent for Axiogenesis AG for the invention of its in vitro assay to screen pharmaceutical drug candidates for effectiveness and safety in treating Hypertrophic Cardiomyopathy (HCM).
The assay, which has previously received patents in Europe and Japan, is based on induced pluripotent stem (iPS) cell technology. Axiogenesis has developed the ability to induce HCM in iPS cell-derived cardiomyocytes, creating an in vitro model of the disease that can be used to evaluate drug candidates and molecular targets.
Hypertrophic Cardiomyopathy, also known as cardiac hypertrophy, is a potentially fatal disease that can develop in as many as 5 in 1,000 people worldwide.
The patent is far-reaching and broadly covers mechanisms for inducing cardiac hypertrophy in any stem cell-derived cardiomyocytes, including Axiogenesis’ Cor.4U® human iPS cell-derived cardiomyocytes and Cor.At® murine stem cell-derived cardiomyocytes.
Read the complete news release.